{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:54:40Z","timestamp":1759366480865,"version":"build-2065373602"},"reference-count":49,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>ABSTRACT.<\/jats:title>\n<jats:p><jats:italic>Shigella<\/jats:italic> infection is a major cause of diarrhea, cognitive and physical stunting, and death in young children in resource-limited settings. A vaccine that is protective against shigellosis is needed. Immune responses that target the O-specific polysaccharide (OSP) of <jats:italic>Shigella<\/jats:italic> spp. are protective against shigellosis. We previously reported the development and evaluation of a conjugate vaccine targeting <jats:italic>Shigella flexneri<\/jats:italic> (<jats:italic>S. flexneri<\/jats:italic>) 3a in mice. Here, we report the evaluation of this vaccine (<jats:italic>Shigella<\/jats:italic> conjugate vaccine <jats:italic>S. flexneri<\/jats:italic> 3a OSP conjugated to a 52 kiloDalton recombinant fragment of the tetanus toxin heavy chain [SCV-Sf3a OSP:rTTHc]) in a second animal model: the guinea pig. This vaccine induced prominent OSP-, lipopolysaccharide-, and rTTHc-specific Immunoglobulin (Ig)G, IgA, and IgM responses in the sera of vaccinated animals. <jats:italic>Shigella<\/jats:italic> conjugate vaccine <jats:italic>S. flexneri<\/jats:italic> 3a also induced serum bactericidal functional antibody responses, and vaccinated guinea pigs were protected against a virulent strain of keratoconjunctival challenge in the standard <jats:italic>Shigella<\/jats:italic> Sereny assay. These results support the further development of SCV-Sf3a OSP:rTTHc.<\/jats:p>","DOI":"10.4269\/ajtmh.25-0269","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T14:24:43Z","timestamp":1754403883000},"page":"737-743","source":"Crossref","is-referenced-by-count":0,"title":["An O-Specific Polysaccharide Shigella flexneri 3a Conjugate Vaccine is Immunogenic and Protective against Virulent Keratoconjunctival Challenge in Guinea Pigs"],"prefix":"10.4269","volume":"113","author":[{"given":"Jeshina","family":"Janardhanan","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chanchal","family":"Wagh","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jibing","family":"Yang","sequence":"additional","affiliation":[{"name":"Center for Comparative Medicine, Massachusetts General Hospital, Boston, Massachusetts;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richelle C.","family":"Charles","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts;"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts;"},{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruchir Kumar","family":"Pansuriya","sequence":"additional","affiliation":[{"name":"International Vaccine Institute, Seoul, South Korea;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahima","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Kaminski","sequence":"additional","affiliation":[{"name":"Latham BioPharm Group, Cambridge, Massachusetts;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashraful Islam","family":"Khan","sequence":"additional","affiliation":[{"name":"International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taufiqur Rahman","family":"Bhuiyan","sequence":"additional","affiliation":[{"name":"International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firdausi","family":"Qadri","sequence":"additional","affiliation":[{"name":"International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavol","family":"Kov\u00e1\u010d","sequence":"additional","affiliation":[{"name":"NIDDK, LBC, National Institutes of Health, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Xu","sequence":"additional","affiliation":[{"name":"NIDDK, LBC, National Institutes of Health, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward T.","family":"Ryan","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts;"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts;"},{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2795","reference":[{"key":"b1","series-title":"Int J Infect Dis","first-page":"78","article-title":"Consequences of Shigella infection in young children: A systematic review","volume":"129","author":"Libby","year":"2023"},{"key":"b2","series-title":"Bull World Health Organ","first-page":"651","article-title":"Global burden of Shigella infections: Implications for vaccine development and implementation of control strategies","volume":"77","author":"Kotloff","year":"1999"},{"key":"b3","series-title":"mSphere","first-page":"e0102021","article-title":"Immunization of rabbits with a quadrivalent Shigella bioconjugate vaccine induces functional antibodies reactive with Shigella isolates from Kenya","volume":"25","author":"Odundo","year":"2022"},{"key":"b4","series-title":"Vaccines (Basel)","first-page":"403","article-title":"Toward a multivalent synthetic oligosaccharide-based conjugate vaccine against Shigella: State-of-the-art for a monovalent prototype and challenges","volume":"10","author":"Phalipon","year":"2022"},{"key":"b5","series-title":"Lancet Infect Dis","first-page":"546","article-title":"Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: A phase 1, dose-escalating, single-blind, randomised, placebo-controlled study","volume":"21","author":"Cohen","year":"2021"},{"key":"b6","series-title":"Vaccine","first-page":"4967","article-title":"Development of Shigella conjugate vaccines targeting Shigella flexneri 2a and S. flexneri 3a using a simple platform-approach conjugation by squaric acid chemistry","volume":"41","author":"Kelly","year":"2023"},{"key":"b7","series-title":"Acta Microbiol Acad Sci Hung","first-page":"367","article-title":"Experimental keratoconjunctivitis shigellosa","volume":"4","author":"Sereny","year":"1957"},{"key":"b8","series-title":"Trends Microbiol","first-page":"917","article-title":"Recent advances in modelling Shigella infection","volume":"32","author":"Miles","year":"2024"},{"key":"b9","series-title":"Infect Immun","first-page":"4075","article-title":"Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains","volume":"59","author":"Hartman","year":"1991"},{"key":"b10","series-title":"Vaccine","first-page":"126263","article-title":"Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge","volume":"42","author":"Kelly","year":"2024"},{"key":"b11","series-title":"Vaccine","first-page":"6936","article-title":"Scalable production and immunogenicity of a cholera conjugate vaccine","volume":"39","author":"Jeon","year":"2021"},{"key":"b12","series-title":"PLoS Negl Trop Dis","first-page":"e0003881","article-title":"A cholera conjugate vaccine containing O-specific polysaccharide (OSP) of V. cholerae O1 inaba and recombinant fragment of tetanus toxin heavy chain (OSP:rTTHc) induces serum, memory and lamina proprial responses against OSP and is protective in mice","volume":"9","author":"Sayeed","year":"2015"},{"key":"b13","series-title":"Vaccine","first-page":"3727","article-title":"Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model","volume":"24","author":"Barry","year":"2006"},{"key":"b14","series-title":"Pathog Dis","first-page":"ftw034","article-title":"Characterization of a multicomponent live, attenuated Shigella flexneri vaccine","volume":"74","author":"DeLaine","year":"2016"},{"key":"b15","series-title":"J Immunol","first-page":"2476","article-title":"New animal model of shigellosis in the Guinea pig: Its usefulness for protective efficacy studies","volume":"178","author":"Shim","year":"2007"},{"key":"b16","series-title":"Mol Biol Res Commun","first-page":"101","article-title":"Immunogenic evaluation of chimeric recombinant protein against ETEC, EHEC and Shigella.","volume":"6","author":"Khalouie","year":"2017"},{"key":"b17","series-title":"Front Microbiol","first-page":"2689","article-title":"Virulence and stress responses of Shigella flexneri regulated by PhoP\/PhoQ","volume":"8","author":"Lin","year":"2017"},{"key":"b18","series-title":"Lancet","first-page":"209","article-title":"Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): A prospective, case-control study","volume":"382","author":"Kotloff","year":"2013"},{"key":"b19","series-title":"Lancet Infect Dis","first-page":"1229","article-title":"Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: The Global Burden of Disease Study 1990-2016","volume":"18","author":"Khalil","year":"2018"},{"key":"b20","series-title":"Lancet Glob Health","first-page":"e564","article-title":"Pathogen-specific burdens of community diarrhoea in developing countries: A multisite birth cohort study (MAL-ED)","volume":"3","author":"Platts-Mills","year":"2015"},{"key":"b21","series-title":"Pediatr Clin North Am","first-page":"799","article-title":"The burden and etiology of diarrheal illness in developing countries","volume":"64","author":"Kotloff","year":"2017"},{"key":"b22","series-title":"Lancet","first-page":"1459","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: A systematic analysis for the Global Burden of Disease Study 2015","volume":"388","year":"2016"},{"key":"b23","series-title":"Int J Mol Sci","first-page":"4329","article-title":"Shigella vaccines: The continuing unmet challenge","volume":"25","author":"Lu","year":"2024"},{"key":"b24","series-title":"Vaccines (Basel)","first-page":"1376","article-title":"The Shigella vaccines pipeline","volume":"10","author":"MacLennan","year":"2022"},{"key":"b25","series-title":"mSphere","first-page":"e0007323","article-title":"Development of the Shigella flexneri 2a, 3a, 6, and S. sonnei artificial Invaplex (InvaplexAR) vaccines","volume":"8","author":"Turbyfill","year":"2023"},{"key":"b26","series-title":"Front Immunol","first-page":"1884","article-title":"A phase 2a randomized study to evaluate the safety and immunogenicity of the 1790GAHB generalized modules for membrane antigen vaccine against Shigella sonnei administered intramuscularly to adults from a shigellosis-endemic country","volume":"8","author":"Obiero","year":"2017"},{"key":"b27","series-title":"Hum Vaccin Immunother","first-page":"1326","article-title":"A phase I trial of WRSS1, a Shigella sonnei live oral vaccine in Bangladeshi adults and children","volume":"15","author":"Raqib","year":"2019"},{"key":"b28","series-title":"Vaccines (Basel)","first-page":"675","article-title":"Detoxified O-specific polysaccharide (O-SP)-protein conjugates: Emerging approach in the Shigella vaccine development scene","volume":"10","author":"Cohen","year":"2022"},{"key":"b29","series-title":"Lancet","first-page":"155","article-title":"Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults","volume":"349","author":"Cohen","year":"1997"},{"key":"b30","series-title":"Pediatr Infect Dis J","first-page":"701","article-title":"Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children","volume":"22","author":"Passwell","year":"2003"},{"key":"b31","series-title":"Vaccines (Basel)","first-page":"33","article-title":"Safety and immunogenicity of a Shigella bivalent conjugate vaccine (ZF0901) in 3-month- to 5-year-old children in China","volume":"10","author":"Mo","year":"2021"},{"key":"b32","series-title":"Vaccines (Basel)","first-page":"212","article-title":"The ongoing journey of a Shigella bioconjugate vaccine","volume":"10","author":"Martin","year":"2022"},{"key":"b33","series-title":"Infect Immun","first-page":"5806","article-title":"Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam","volume":"67","author":"Kossaczka","year":"1999"},{"key":"b34","series-title":"Lancet Infect Dis","first-page":"85","article-title":"Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance","volume":"1","author":"Klugman","year":"2001"},{"key":"b35","series-title":"J Infect Dis","first-page":"982","article-title":"Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine","volume":"164","author":"Takala","year":"1991"},{"key":"b36","series-title":"Emerg Infect Dis","first-page":"806","article-title":"Carriage rate and effects of vaccination after outbreaks of serogroup C meningococcal disease, Brazil, 2010","volume":"20","author":"S\u00e1fadi","year":"2014"},{"key":"b37","series-title":"Am J Trop Med Hyg","first-page":"1122","article-title":"Vaccination of rabbits with a cholera conjugate vaccine comprising O-specific polysaccharide and a recombinant fragment of tetanus toxin heavy chain induces protective immune responses against Vibrio cholerae O1","volume":"109","author":"Kelly","year":"2023"},{"key":"b38","series-title":"Chemistry","first-page":"12946","article-title":"Isolation, purification, characterization and direct conjugation of the lipid A-free lipopolysaccharide of Vibrio cholerae O139","volume":"25","author":"Xu","year":"2019"},{"key":"b39","series-title":"Chembiochem","first-page":"799","article-title":"Conjugate vaccines from bacterial antigens by squaric acid chemistry: A closer look","volume":"18","author":"Xu","year":"2017"},{"key":"b40","series-title":"PLoS Negl Trop Dis","first-page":"e2683","article-title":"Evaluation in mice of a conjugate vaccine for cholera made from Vibrio cholerae O1 (Ogawa) O-specific polysaccharide","volume":"8","author":"Alam","year":"2014"},{"key":"b41","series-title":"Bioconjug Chem","first-page":"2179","article-title":"Simple, direct conjugation of bacterial O-SP-core antigens to proteins: Development of cholera conjugate vaccines","volume":"22","author":"Xu","year":"2011"},{"key":"b42","series-title":"Clin Infect Dis","first-page":"933","article-title":"Shigella isolates from the global enteric multicenter study inform vaccine development","volume":"59","author":"Livio","year":"2014"},{"key":"b43","series-title":"Nat Rev Microbiol","first-page":"540","article-title":"Clinical trials of Shigella vaccines: Two steps forward and one step back on a long, hard road","volume":"5","author":"Levine","year":"2007"},{"key":"b44","series-title":"Front Immunol","first-page":"574057","article-title":"Vi-vaccinations induce heterogeneous plasma cell responses that associate with protection from typhoid fever","volume":"11","author":"Cross","year":"2020"},{"key":"b45","series-title":"Microorganisms","first-page":"1675","article-title":"Herd protection against meningococcal disease through vaccination","volume":"8","author":"Clark","year":"2020"},{"key":"b46","series-title":"Lancet Microbe","first-page":"100889","article-title":"Determinants of immune responses predictive of protection against shigellosis in an endemic zone: A systems analysis of antibody profiles and function","volume":"5","author":"Bernshtein","year":"2024"},{"key":"b47","series-title":"Clin Vaccine Immunol","first-page":"e00412","article-title":"Functional and antigen-specific serum antibody levels as correlates of protection against shigellosis in a controlled human challenge study","volume":"24","author":"Shimanovich","year":"2017"},{"key":"b48","series-title":"Curr Trop Med Rep","first-page":"81","article-title":"Shigella: A highly virulent and elusive pathogen","volume":"1","author":"Zaidi","year":"2014"},{"key":"b49","series-title":"FEMS Microbiol Rev","first-page":"43","article-title":"Shigella flexneri infection: Pathogenesis and vaccine development","volume":"28","author":"Jennison","year":"2004"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/113\/4\/article-p737.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/113\/4\/article-p737.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/113\/4\/article-p737.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T17:29:45Z","timestamp":1759339785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/113\/4\/article-p737.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":49,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.25-0269","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"type":"print","value":"0002-9637"},{"type":"electronic","value":"1476-1645"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}